Collectionner le produit
Détails du produit
Synonyms
ADAM17, TACE, CD156b
Source
Human ADAM17 Protein, His Tag (AD7-H53H3) is expressed from CHO cells. It contains AA Arg 215 - Asn 671 (Accession # P78536-1).
Predicted N-terminus: Arg 215
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 53.1 kDa. The protein migrates as 60-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>80% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM Tris, 500 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human ADAM17 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 80% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity
Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2. The specific activity is >800 pmol/min/µg (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Disintegrin and metalloproteinase domain-containing protein 17
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
2 Détails
- Étape de développement la plus élevée：
Phase 1 Clinical
Contact Us
Drug Candidate Licensing
